> top > docs > PMC:7530350 > spans > 83-1902 > annotations

PMC:7530350 / 83-1902 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T3 108-116 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T4 138-151 Body_part denotes interleukin-6 http://purl.org/sig/ont/fma/fma264829
T5 1114-1119 Body_part denotes serum http://purl.org/sig/ont/fma/fma63083

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 1114-1119 Body_part denotes serum http://purl.obolibrary.org/obo/UBERON_0001977

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T2 26-34 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T3 53-65 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166
T4 235-243 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T5 445-453 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T6 660-668 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T7 713-721 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T8 1511-1519 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T9 1675-1683 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T10 1775-1783 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T3 95-96 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T4 138-151 http://purl.obolibrary.org/obo/PR_000001393 denotes interleukin-6
T5 375-376 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T6 464-465 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T7 976-980 http://purl.obolibrary.org/obo/UBERON_0003101 denotes male
T8 976-980 http://www.ebi.ac.uk/efo/EFO_0000970 denotes male
T9 1189-1190 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T10 1216-1218 http://purl.obolibrary.org/obo/CLO_0008426 denotes pg
T11 1470-1471 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 82-93 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T2 153-155 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T4 367-369 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T6 386-395 Chemical denotes indicator http://purl.obolibrary.org/obo/CHEBI_47867
T7 612-614 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T9 876-881 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T10 946-951 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T11 976-980 Chemical denotes male http://purl.obolibrary.org/obo/CHEBI_30780
T12 995-1000 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T13 1039-1044 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T14 1130-1132 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T16 1149-1154 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T17 1178-1183 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T18 1391-1393 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T20 1502-1504 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T22 1642-1644 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T24 1766-1768 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
13 138-151 Gene denotes interleukin-6 Gene:3569
14 367-371 Gene denotes IL-6 Gene:3569
15 214-222 Species denotes patients Tax:9606
16 422-430 Species denotes patients Tax:9606
17 82-93 Chemical denotes tocilizumab MESH:C502936
18 26-34 Disease denotes COVID-19 MESH:C000657245
19 47-65 Disease denotes hyper-inflammation MESH:D007249
20 235-243 Disease denotes COVID-19 MESH:C000657245
21 445-453 Disease denotes COVID-19 MESH:C000657245
30 612-616 Gene denotes IL-6 Gene:3569
31 1130-1134 Gene denotes IL-6 Gene:3569
32 1391-1395 Gene denotes IL-6 Gene:3569
33 627-635 Species denotes patients Tax:9606
34 682-690 Species denotes patients Tax:9606
35 800-808 Species denotes patients Tax:9606
36 660-668 Disease denotes COVID-19 MESH:C000657245
37 713-721 Disease denotes COVID-19 MESH:C000657245
45 1502-1506 Gene denotes IL-6 Gene:3569
46 1642-1646 Gene denotes IL-6 Gene:3569
47 1766-1770 Gene denotes IL-6 Gene:3569
48 1661-1669 Species denotes patients Tax:9606
49 1511-1519 Disease denotes COVID-19 MESH:C000657245
50 1675-1683 Disease denotes COVID-19 MESH:C000657245
51 1775-1783 Disease denotes COVID-19 MESH:C000657245

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T1 53-65 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation
T2 1642-1657 http://purl.obolibrary.org/obo/GO_0032635 denotes IL-6 production

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T3 0-10 Sentence denotes Background
T4 11-66 Sentence denotes Evidence links COVID-19 severity to hyper-inflammation.
T5 67-244 Sentence denotes Treatment with tocilizumab, a monoclonal antibody directed against the interleukin-6 (IL-6) receptor, was shown to lead to clinical improvement in patients with severe COVID-19.
T6 245-454 Sentence denotes We, therefore, performed the present systematic review and meta-analysis to investigate whether the circulating levels of IL-6 is a reliable indicator of disease severity among patients affected with COVID-19.
T7 456-463 Sentence denotes Methods
T8 464-570 Sentence denotes A systematic search was conducted in PubMed, Scopus, Web of Science, and Google Scholar on April 19, 2020.
T9 572-579 Sentence denotes Results
T10 580-735 Sentence denotes Eleven studies provided data of IL-6 levels in patients with severe to critical COVID-19 (severe) and patients with mild to moderate COVID-19 (non-severe).
T11 736-790 Sentence denotes The included studies were of moderate to high quality.
T12 791-952 Sentence denotes The mean patients’ age was 60.9 years, ranging from 45.2 to 76.7 years in the severe group and 46.8 years, ranging from 37.9 to 61 years, in the nonsevere group.
T13 953-1045 Sentence denotes Fifty-two percent were male in the severe group, as compared to 46% in the non-severe group.
T14 1046-1230 Sentence denotes An overall random effects meta-analysis showed significantly higher serum levels of IL-6 in the severe group than in the non-severe group with a mean difference of +23.1 pg/mL (95% CI:
T15 1231-1293 Sentence denotes 12.42–33.79) and the overall effect of 4.24 (P-value < 0.001).
T16 1294-1415 Sentence denotes Meta-regressions showed that neither age nor sex significantly influenced the mean difference of IL-6 between the groups.
T17 1417-1428 Sentence denotes Conclusions
T18 1429-1557 Sentence denotes Meta-analysis and meta-regression reveal a reliable relationship between IL-6 and COVID-19 severity, independent of age and sex.
T19 1558-1684 Sentence denotes Future research is, however, required to assess the effect of BMI on the pattern of IL-6 production in patients with COVID-19.
T20 1685-1819 Sentence denotes Also, there might be confounding factors that influence the relationship between IL-6 and COVID-19 severity and remain as yet unknown.